Some studies have demonstrated a lower expression of Th1 cytokines, a shift to a Th2 cytokine profile [4,15], and a decrease in cytotoxic CD8+ T cell counts along ACS [17,18], whereas others have suggested an increase in the density of T lymphocytes, regulatory T cells, and macrophages during tumor progression [4,14,16]. The gene discussed is CD8A; the disease is neoplasm.